Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guardant Health Launches Liquid Biopsy Test For Detecting Colorectal Cancer Recurrence

Executive Summary

Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.

You may also be interested in...



Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults

The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.

Minute Insight: Agendia Collaborates With Illumina And Brazilian Health Care Providers

The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.

Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test

Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT143506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel